Angiotensin-converting enzyme inhibition but not β-adrenergic blockade limits transforming growth factor-β overexpression in acute normotensive anti-thy1 glomerulonephritis

Journal of Hypertension

Volumn 21, Issue 4, 2003, Pages 771-780

  Peters, Harm ^a   Rückert, Matthias ^a   Gaedeke, Jens ^a   Liefeldt, Lutz ^a   Ketteler, Markus ^b   Sharma, Arya M ^a   Neumayer, Hans H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Angiotensin converting inhibitors; Fibrosis; Transforming growth factor ; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRONECTIN; METOPROLOL; NEBIVOLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; GLOMERULONEPHRITIS; HEART RATE; HISTOLOGY; HYPERTENSION; KIDNEY FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0038031720     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200304000-00021     Document Type: Conference Paper

References (35)

1. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
2. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346:371-374.
3. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De-La-Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97:8015-8020.
4. Peters H, Noble NA, Border WA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54:1575-1583.
5. Peters H, Border WA, Noble NA. Angiotensin II blockade and low protein diet produce additive therapeutic effects on experimental glomerulonephritis. Kidney Int 1999; 57:1493-1501.
6. Peters H, Border WA, Noble NA. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 2000; 57:922-1001.
7. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318:1657-1666.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
9. Border WA, Noble NA. Interactions of TGF-beta and angiotensin II in renal fibrosis. Hypertension 1998; S31:181-188.
10. Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 1998; 13:1131-1142.
11. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 2001; 135: 153-160.
12. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11:1469-1478.
13. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001; 60:1309-1323.
14. Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12:602-605.
15. Wenzel UO, Wolf G, Thaiss F, Helmchen U, Stahl RA. Renovascular hypertension does not influence repair of glomerular lesions induced by anti-thymocyte glomerulonephritis. Kidney Int 2000; 58:1135-1147.
16. Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986; 31:376-429.
17. Janssens WJ. Pharmacology of nebivolol. J Pharm Belg 1992; 47:323-327.
18. Magnotti RA, Stephens GW, Rogers RK, Pesce AJ. Microplate measurement of urinary albumin and creatinine. Clin Chem 1989; 35:1371-1375.
19. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG. Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 1980; 104:205-214.
20. Pavenstadt H. New aspects concerning the role of catecholamines in the pathogenesis of glomerular disease. Nephrol Dial Transplant 1998; 13:1916-1919.
21. Bobik A, Grinpukel S, Little PJ, Grooms A, Jackman G. Angiotensin II and noradrenaline increase PDGF-BB receptors and potentiate PDGF-BB stimulated DNA synthesis in vascular smooth muscle. Biochem Biophys Res Commun 1990; 166:580-588.
22. Boero R, Pignataro A, Ferro M, Quarello F. Sympathetic nervous system and chronic renal failure. Clin Exp Immunol 2001; 23:69-75.
23. Hasko G, Shanley TP, Egnaczyk G, Nemeth ZH, Salzman AL, Vizi ES, Szabo C. Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism. Br J Pharmacol 1998; 125:1297-1303.
24. Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T. Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine 1999; 11:759-765.
25. Fisher SA, Absher M. Norepinephrine and ANG II stimulate secretion of TGF-beta by neonatal rat cardiac fibroblasts in vitro. Am J Physiol 1995; 268:C910-C917.
26. Peters H, Border WA, Noble NA, Angiotensin II and L-arginine in tissue fibrosis: more than blood pressure. Kidney Int 1997; 51:1481-1486.
27. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197.
28. Wallin JD. Adrenoreceptors and renal function. J Clin Hypertens 1985; 1:171-178.
29. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26:861-865.
30. Benigni A, Perico N, Remuzzi G. Endothelin antagonists and renal protection. J Cardiovasc Pharmacol 2000; 35:S75-S78.
31. Peters H, Border WA, Noble NA. From rats to men: a perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 1999; 14:1640-1650.
32. Hoffman BB, Lefkowitz RJ, Taylor P. Neurotransmission: the autonomic and somatic motor nervous system. In: Hardman JG, Limbird LE (editors): Goodman & Gilman's the pharmacological basis of therapeutics, 9th edition. New York: McGraws-Hill; 1995, pp. 105-139.
33. Taylor P. Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE (editors): Goodman & Gilman's the pharmacological basis of therapeutics, 9th edition. New York: McGraws-Hill; 1995, pp 781-808.
34. Zoja C, Abbate M, Corna D, Capitanio M, Donadelli R, Bruzzi I, et al. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 1998; 31:453-463.
35. Peters H, Border WA, Noble NA. Angiotensin blockade reduces glomerular TGF-beta1 and matrix protein synthesis in normal rats [abstract]. J Am Soc Nephrol 1998; g:506A.